Study Contact Information:
Principal Investigator: Johanna Bendell, MD
Sarah Cannon Research Institute
by phone 844-710-6157 or by email
Medicines that affect bacteria in the stomach and intestines may assist immunotherapy agents like pembrolizumab (Keytruda) in treating cancer. This study will look at the effect of a drug, EDP1503 on enhancing the anti-cancer response when used with pembrolizumab, in patients with advanced metastatic colorectal carcinoma, triple-negative breast cancer, or cancers that have recurred after a type of immunotherapy known as an immune checkpoint inhibitor. NOTE: This this study is no longer enrolling patients.
This is a Phase 1/2 non-randomized, open-label study. Patients will be assigned to one of three groups based on their type of cancer. All patients will know which group they are assigned to and the medications that they are receiving.
All patients in this study will receive EDP1503 orally for a period of 14 days, following which they will be given a combination of EDP1503 orally and the immunotherapy agent pembrolizumab. Pembrolizumab will be administered intravenously once every 3 weeks.
Participants will be followed for 2 years.
For more information at all sites contact Sarah Cannon Research Institute by phone 844-710-6157 or by email
NOTE: This this study is no longer enrolling patients.
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.